Oppenheimer analyst Kostas Biliouris says Sarepta’s (SRPT) myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy data “appear promising.” However, the early nature of data and use of different sample sizes across measurements may bias the results, preventing conclusion, the analyst tells investors in a research note. The firm awaits additional data in the second half of 2026 to better assess Sarepta’s programs. Oppenheimer points out that Sarepta’s mean muscle concentration under 1mg/kg is significantly higher even than Avidity’s highest individual concentrations under 4mg/kg. The firm has an Outperform rating on Sarepta with a $37 price target The stock in morning trading is up 23%, or $4.01, to $21.62.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade SRPTPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta announces first clinical data from pipeline targeting FSHD1, DM1
- Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential
- Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
- Sarepta provides regulatory update on Amondys 45, Vyondys 53
- Sarepta begins screening, enrollment in Cohort 8 of ENDEAVOR study